INHIBITORS OF APOL1 AND METHODS OF USING SAME
The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in...
Saved in:
Main Authors | , , , , , , , , , , , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
03.03.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).
L'invention concerne au moins une entité choisie parmi des composés de formule I, un tautomère associé, un dérivé deutéré de ce composé ou tautomère, et un sel pharmaceutiquement acceptable de l'un quelconque de ceux-ci ; des compositions les comprenant ; et des méthodes d'utilisation de celles-ci, notamment des utilisations dans le traitement de maladies à médiation assurée par APOL1, notamment le cancer du pancréas, la glomérulosclérose segmentaire et focale (FSGS), et/ou une néphropathie rénale non diabétique (NDKD). |
---|---|
Bibliography: | Application Number: CA20213190609 |